Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial

Andrés Poveda*, Anne Floquet, SOLO2/ENGOT-Ov21 investigators, Jonathan A. Ledermann, Rebecca Asher, Richard T. Penson, Amit M. Oza, Jacob Korach, Tomasz Huzarski, Sandro Pignata, Michael Friedlander, Alessandra Baldoni, Tjoung Won Park-Simon, Kenji Tamura, Gabe S. Sonke, Alla Lisyanskaya, Jae Hoon Kim, Elias Abdo Filho, Tsveta Milenkova, Elizabeth S. LowePhil Rowe, Ignace Vergote, Eric Pujade-Lauraine

*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

188 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial'. Together they form a unique fingerprint.

Medicine and Dentistry